¶ Alpha-Lipoic Acid
| Type | Organosulfur Compound |
| Active Cmpd | R-Alpha-Lipoic Acid |
| Source | Endogenous, Organ Meats, Spinach |
| Dose Range | 300–600 mg/day |
| Half-life | ~30 minutes |
| Main Benefit | Neuropathy, Glycemic Control |
| Absorption | Variable (Food reduces by ~30%) |
Alpha-Lipoic Acid (ALA) is a naturally occurring, organosulfur mitochondrial coenzyme that plays a fundamental role in glucose metabolism and cellular antioxidant defense. Boasting an extensive body of high-quality human evidence, ALA is widely utilized in clinical neurology and metabolic medicine to mitigate diabetic peripheral neuropathy and improve insulin sensitivity.
¶ At a glance
Aliases
- Also known as: Thioctic acid, 1,2-dithiolane-3-pentanoic acid
- Chemical / botanical name: Alpha-Lipoic Acid ()
- Category: Mitochondrial coenzyme / Organosulfur antioxidant
Key points (high-level summary)
- Neuropathy & Pain: In adults with diabetic peripheral neuropathy, 600 mg of ALA daily significantly reduces burning, numbness, and stabbing pain by improving nerve blood flow and reducing oxidative damage.[1][2]
- Metabolic Health: ALA supplementation dose-dependently lowers fasting blood glucose, HbA1c, and insulin resistance (HOMA-IR), making it a potent adjunct for metabolic syndrome and type 2 diabetes.[3][4]
- Antioxidant Network: Unlike most antioxidants, ALA is both water- and fat-soluble, allowing it to regenerate other depleted antioxidants like Vitamin C, Vitamin E, and glutathione across all cellular compartments.[5][6]
- Safety & Limitations: Generally well-tolerated, but the biologically active "R" form (R-ALA) is superior to the common racemic mixture. High doses may cause mild GI upset or symptomatic hypoglycemia in diabetics.[7]
What people use it for
- Main goals: Diabetic neuropathy, glycemic control, weight management, mitochondrial support, and liver health (NAFLD).
- Evidence quality (overall): High (based on numerous Cochrane reviews and large-scale meta-analyses).
¶ What is Alpha-Lipoic Acid?
Alpha-Lipoic Acid is a fatty acid derivative that contains two sulfur atoms, allowing it to undergo rapid redox cycling. While the human body synthesizes small amounts endogenously, these levels are sufficient only for its role as a metabolic cofactor, not for systemic antioxidant or therapeutic effects, necessitating exogenous supplementation.
- Definition: A disulfide-containing compound that serves as an essential cofactor for mitochondrial multi-enzyme complexes involved in energy production.
- Natural sources: Found in trace amounts in animal tissues (heart, liver, kidney) and some vegetables (spinach, broccoli, Brussels sprouts). However, dietary ALA is covalently bound to proteins and does not yield significant free ALA in the blood.[8]
- Traditional / historical use: Discovered in 1951 and initially classified as a vitamin, it was later recognized as a coenzyme. It has been a standard pharmaceutical treatment for diabetic neuropathy in Germany since the 1960s.
- Current regulatory status: Available as an over-the-counter dietary supplement in the US and UK; regulated as a prescription drug for neuropathy in several European countries (e.g., Germany).
- Key pharmacological property: "Universal" antioxidant and insulin-sensitizing mitochondrial cofactor.
¶ What are Alpha-Lipoic Acid’s main benefits?
ALA offers a diverse range of benefits, with its clinical utility centered on neuroprotection and metabolic regulation.
- Neuropathic Pain Relief: Clinical trials consistently show that 600 mg/day of ALA (oral or IV) significantly reduces the Total Symptom Score (TSS) in diabetic polyneuropathy, alleviating burning and lancinating pain.[2:1][9]
- Glycemic Regulation: Meta-analyses of oral supplementation show robust reductions in fasting plasma glucose (-1.0 to -1.5 mmol/L) and HbA1c levels in type 2 diabetics.[3:1][10]
- Weight & BMI Management: Supplementation significantly reduces body weight and BMI in overweight adults, likely through AMPK activation and suppression of hypothalamic appetite signaling.[11][12]
- Liver Health (NAFLD): ALA reduces hepatic fat accumulation and lowers liver enzymes (ALT, AST) in patients with non-alcoholic fatty liver disease by mitigating lipotoxicity.[13][14]
- Cardiovascular Function: ALA improves endothelial function (flow-mediated dilation) and reduces systolic and diastolic blood pressure by approximately 5–10 mmHg.[15][16]
- Anti-Inflammatory Action: It significantly lowers systemic markers of inflammation, including C-reactive protein (CRP), IL-6, and TNF-alpha.[17][18]
¶ Evidence summary table (human outcomes)
| Outcome / Goal | Effect | Consistency | Evidence quality | Trials | Notes (population, duration, dose) |
|---|---|---|---|---|---|
| Neuropathic Symptoms | High | High | 15+ RCTs | 600 mg/day significantly reduces pain/burning in DPN[2:2][9:1] | |
| Fasting Blood Glucose | High | High | 20+ RCTs | Significant reductions across T2DM and metabolic syndrome[3:2][10:1] | |
| HbA1c Levels | High | Moderate | 12 RCTs | 300–600 mg/day for 8–12 weeks improves long-term glycemia[19][4:1] | |
| Body Weight | Moderate | Moderate | 10 RCTs | Modest but statistically significant loss (~1.27 kg)[11:1][12:1] | |
| C-Reactive Protein (CRP) | High | High | 11 RCTs | Potent systemic anti-inflammatory effect at 600 mg/day[17:1][20] | |
| Endothelial Function (FMD) | Moderate | Moderate | 6 RCTs | Improves vascular reactivity and nitric oxide bioactivity[16:1] | |
| Liver Enzymes (ALT/AST) | Moderate | Moderate | 5 RCTs | Reduces hepatic inflammation and fat in NAFLD patients[13:1][14:1] | |
| Sperm Concentration | Moderate | Moderate | 4 RCTs | Improves male fertility parameters via oxidative stress reduction[21][22] | |
| PCOS Symptoms | Moderate | Low | 3 RCTs | Improves hyperandrogenism and insulin sensitivity in PCOS[23] |
LongeviData outcomes widget (required)
¶ How does Alpha-Lipoic Acid work?
ALA acts as a "metabolic switch" that optimizes energy production while providing a multi-layered antioxidant defense.
- Primary targets:
- Pyruvate Dehydrogenase (PDH): ALA is an essential coenzyme for the E2 subunit, facilitating the entry of glucose-derived pyruvate into the Krebs cycle for ATP production.[8:1]
- Nrf2 Pathway: Activates the master transcription factor for endogenous antioxidant production, upregulating glutathione synthesis.[5:1]
- AMPK: Stimulates AMP-activated protein kinase, mimicking the metabolic effects of exercise.[11:2]
- Core mechanisms:
- Antioxidant Recycling Hub: ALA and its reduced form, dihydrolipoic acid (DHLA), form a powerful redox couple. They can directly neutralize reactive oxygen species (ROS) and, crucially, donate electrons to "recharge" oxidized Vitamin C, Vitamin E, and Glutathione back to their active forms.[5:2][6:1]
- Insulin Mimicry: ALA stimulates the translocation of GLUT4 glucose transporters to the cell membrane, enhancing glucose uptake independently of insulin signaling.[8:2]
- Metal Chelation: ALA binds and inactivates transition metals (like free iron and copper) that otherwise catalyze the formation of highly toxic hydroxyl radicals.[24]
- Evidence source:
- Human data: Mechanisms of glycemic control and antioxidant recycling are well-validated in human tracer and biomarker studies.[8:3][10:2]
- Animal data: Anti-aging effects, senolytic properties, and protection against traumatic brain injury (TBI) are primarily based on high-impact rodent models.[25][^44]
- Pharmacokinetics:
- Bioavailability: Oral absorption is rapid but incomplete (~30%). The "R" isomer is more bioavailable than the "S" isomer.[2:3]
- Half-life: Extremely short (~30 minutes). Clinical effects depend on the transient peak concentration rather than steady-state levels.[2:4]
- Food Effect: Taking ALA with food reduces absorption by approximately 30%; it should be taken on an empty stomach.[2:5]
¶ Effects on different systems
¶ Metabolic health (glucose, insulin, lipids)
ALA is a potent insulin sensitizer. It enhances glucose disposal by activating the insulin receptor signaling pathway and stimulating GLUT4 translocation. In meta-analyses, it has been shown to reduce fasting insulin, HOMA-IR, and triglycerides, while increasing HDL-cholesterol in patients with metabolic syndrome.[3:3][4:2][26]
¶ Neurological health (neuropathy, neuroprotection)
ALA is the only supplement with "High" certainty evidence for treating diabetic peripheral neuropathy. It improves nerve microcirculation, increases nerve conduction velocity, and reduces oxidative stress within the vasa nervorum.[1:1][2:6] Beyond diabetes, emerging evidence suggests ALA may slow brain atrophy in secondary progressive multiple sclerosis and provide neuroprotection following traumatic brain injury.[27][25:1]
¶ Cardiovascular health
By improving endothelial function and reducing systemic inflammation (CRP), ALA supports vascular health. It has been shown to modestly lower blood pressure and improve arterial stiffness in overweight adults.[15:1][16:2]
¶ Liver & Renal health
In patients with NAFLD, ALA supplementation reduces liver fat and inflammation.[13:2] It also exhibits nephroprotective effects in diabetic patients, reducing albuminuria and slowing the progression of diabetic nephropathy when combined with standard care (e.g., valsartan).[28][29]
¶ Reproductive health
ALA improves sperm concentration, motility, and morphology in subfertile men.[21:1] In women, it is used to manage PCOS and has been studied for reducing the risk of miscarriage by stabilizing the subchorionic space.[30][31]
¶ Dosage and how to take it
Standard dosing in studies
- Diabetic Neuropathy: 600 mg per day. Higher doses (1,200–1,800 mg) do not appear to provide additional benefit but increase side effects.[2:7]
- Metabolic Health / Weight Loss: 300 to 600 mg per day.
- PCOS / Fertility: 400 to 600 mg per day.
- Intravenous (IV) Use: Clinical protocols often begin with 600 mg/day IV for 2–3 weeks before transitioning to oral maintenance.[2:8]
Forms and bioavailability
- R-Lipoic Acid (R-ALA): The naturally occurring, biologically active form. It is more expensive but significantly more bioavailable and effective than the "S" form.
- Na-R-ALA: The sodium salt of R-ALA; it is more heat-stable and has much higher peak plasma concentrations than pure R-ALA.
- S-Lipoic Acid (S-ALA): A synthetic byproduct found in 50/50 "Alpha-Lipoic Acid" (racemic) mixtures. It may compete with the R-form and is generally considered less effective.
Special populations
- Diabetics: Must monitor blood glucose closely, as ALA may necessitate a reduction in insulin or oral hypoglycemic dosage.
- Thiamine Deficiency: ALA can interfere with thiamine (B1) metabolism. Chronic alcohol users or those with B1 deficiency should supplement with thiamine when taking high-dose ALA.[8:4]
- Pregnancy: Studied at 400–600 mg/day for specific indications (e.g., subchorionic hematoma) with a good safety profile, but should only be used under medical supervision.[31:1]
¶ Safety and side effects
Common side effects
- GI Upset: Nausea, vomiting, and acid reflux are the most common complaints, typically at doses >600 mg.
- Skin Rash: Allergic dermatitis or urticaria can occur in sensitive individuals.
- Sulfurous Odor: High doses may impart a sulfur-like smell to the urine, similar to asparagus.
Less common / serious concerns
- Hypoglycemia: Significant risk of low blood sugar in patients on insulin or sulfonylureas.[7:1]
- Insulin Autoimmune Syndrome (Hirata Disease): A rare genetic reaction where ALA triggers the production of insulin antibodies, leading to severe, unpredictable hypoglycemia.[8:5]
- Iron Depletion: ALA has mild iron-chelating properties; long-term high-dose use may lower ferritin levels in susceptible individuals.[32]
Who should be especially cautious or avoid it
- Patients with uncontrolled thiamine deficiency.
- Individuals with a known genetic predisposition to Insulin Autoimmune Syndrome.
- Patients undergoing chemotherapy, as high-dose antioxidants may theoretically interfere with pro-oxidant treatments.
LongeviData safety widget (required)
¶ Drug and supplement interactions
Pharmacokinetic interactions
- Metal Cations: ALA can chelate minerals like calcium, magnesium, and iron. Separate ALA from mineral supplements or antacids by at least 2 hours.[32:1][24:1]
- Biotin: ALA and Biotin compete for the same transport mechanism (SMVT); high doses of one may theoretically reduce the uptake of the other.[8:6]
Pharmacodynamic interactions
- Antidiabetic Drugs: Synergistic effect on blood glucose lowering. Combining with Metformin, insulin, or GLP-1 agonists increases hypoglycemia risk.
- Thyroid Medications: ALA may decrease the conversion of T4 to T3; patients on levothyroxine should monitor thyroid labs (TSH).
- Antiseizure Drugs: Rodent models suggest ALA may synergize with certain antiseizure medications to reduce oxidative brain damage.[^42]
¶ Combining Alpha-Lipoic Acid with other supplements (“stacks”)
- The Metabolic Stack: ALA (600mg) + Metformin (or Berberine). Targets multiple pathways of insulin sensitivity and AMPK activation.
- The Neuropathy Stack: ALA (600mg) + Benfotiamine (300-600mg) + Acetyl-L-Carnitine. This "triple threat" addresses glycation, oxidative stress, and nerve energy metabolism.[8:7][^53]
- The Master Antioxidant Stack: ALA (300-600mg) + Glutathione (or NAC) + Vitamin C + Vitamin E. Utilizes the "redox network" where ALA recycles all other members.[5:3]
¶ Practical questions (FAQ)
¶ How long does it take for Alpha-Lipoic Acid to work for neuropathy?
For neuropathic pain, significant improvements are typically observed within 3 to 5 weeks of consistent daily dosing (600 mg). Intravenous administration can produce faster results (within 10–14 days).[2:9][9:2]
¶ Is R-Lipoic Acid really worth the extra cost?
Yes, for clinical conditions like neuropathy. R-ALA is the only form recognized by the body’s enzymes. It achieves much higher plasma peaks and is roughly 2–10 times more potent than the synthetic S-form found in racemic mixtures.[8:8][2:10]
¶ Should I take ALA with food?
No. Food significantly interferes with ALA absorption. For maximum bioavailability, take it on an empty stomach, at least 30 minutes before a meal or 2 hours after.[2:11]
¶ Does ALA help with weight loss?
ALA provides a modest weight loss effect (approx. 1.27 kg more than placebo over 12–24 weeks). It is best used as a metabolic metabolic "primer" rather than a primary fat burner.[11:3][12:2]
¶ Is it different from the ALA in flaxseeds?
Yes. This is a frequent point of clinical confusion. Alpha-Lipoic Acid is a mitochondrial antioxidant. Alpha-Linolenic Acid (also abbreviated ALA) is an Omega-3 fatty acid found in flax and walnuts. They are chemically and functionally distinct.
¶ How we evaluated the evidence
Evidence for Alpha-Lipoic Acid was evaluated using the GRADE framework.
- Study types: Prioritized systematic reviews and meta-analyses (Cochrane, BMJ, Nutrients) and large-scale RCTs.
- Evidence Grading:
- High Quality: Diabetic peripheral neuropathy and glycemic control outcomes are supported by extensive, consistent evidence from multiple meta-analyses and systematic reviews.
- Moderate Quality: Weight loss, lipid profiles, and liver enzyme reductions are statistically significant but show some heterogeneity or smaller clinical effect sizes.
- Low Quality: Benefits for PCOS and specific male fertility parameters are based on fewer or smaller trials.
¶ References
Hsieh RY, et al. (2023). Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Nutrients. https://pubmed.ncbi.nlm.nih.gov/37630823/ ↩︎ ↩︎
Baicus C, et al. (2024). Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/38205823/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Jibril AT, et al. (2022). Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized trials. Endocrine Connections. https://pubmed.ncbi.nlm.nih.gov/36006850/ ↩︎ ↩︎ ↩︎ ↩︎
Ebada MA, et al. (2019). Efficacy of Alpha-lipoic Acid in The Management of Diabetes Mellitus: A Systematic Review and Meta-analysis. Iranian Journal of Pharmaceutical Research. https://pubmed.ncbi.nlm.nih.gov/32184879/ ↩︎ ↩︎ ↩︎
Shanaida M, et al. (2025). Alpha-lipoic Acid: An Antioxidant with Anti-aging Properties for Disease Therapy. Current Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/38644711/ ↩︎ ↩︎ ↩︎ ↩︎
Khan H, et al. (2022). α-Lipoic Acid, an Organosulfur Biomolecule a Novel Therapeutic Agent for Neurodegenerative Disorders: An Mechanistic Perspective. Neurochemical Research. https://pubmed.ncbi.nlm.nih.gov/35445914/ ↩︎ ↩︎
Fogacci F, et al. (2020). Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Antioxidants. https://pubmed.ncbi.nlm.nih.gov/33086555/ ↩︎ ↩︎
Ciubotaru A, et al. (2026). Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. Nutrients. https://pubmed.ncbi.nlm.nih.gov/42196997/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Wang X, et al. (2018). Alpha lipoic acid combined with epalrestat: a therapeutic option for patients with diabetic peripheral neuropathy. Drug Design, Development and Therapy. https://pubmed.ncbi.nlm.nih.gov/30233145/ ↩︎ ↩︎ ↩︎
Mahmoudi-Nezhad M, et al. (2021). An updated systematic review and dose-response meta-analysis of the effects of α-lipoic acid supplementation on glycemic markers in adults. Nutrition. https://pubmed.ncbi.nlm.nih.gov/33199187/ ↩︎ ↩︎ ↩︎
Luo Y, et al. (2025). Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis. BMJ Open. https://pubmed.ncbi.nlm.nih.gov/40180416/ ↩︎ ↩︎ ↩︎ ↩︎
Vajdi M, et al. (2020). Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials. International Journal of Clinical Practice. https://pubmed.ncbi.nlm.nih.gov/32091656/ ↩︎ ↩︎ ↩︎
Saeed TN, et al. (2026). Effects of alpha-lipoic acid in non-alcoholic fatty liver disease (NAFLD): a systematic review of literature. Journal of Diabetes and Metabolic Disorders. https://pubmed.ncbi.nlm.nih.gov/42368730/ ↩︎ ↩︎ ↩︎
Li T, et al. (2026). Effects of alpha-lipoic acid supplementation on patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized clinical trials. BMC Endocrine Disorders. https://pubmed.ncbi.nlm.nih.gov/41917882/ ↩︎ ↩︎
Vajdi M, et al. (2023). The effects of alpha lipoic acid (ALA) supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine. https://pubmed.ncbi.nlm.nih.gov/37942070/ ↩︎ ↩︎
Jalilpiran Y, et al. (2021). The effect of Alpha-lipoic acid supplementation on endothelial function: A systematic review and meta-analysis. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/33205568/ ↩︎ ↩︎ ↩︎
Đukić L, et al. (2022). The Effect of α-lipoic Acid on C-Reactive Protein Level: A Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Studies. Dose-Response. https://pubmed.ncbi.nlm.nih.gov/36262716/ ↩︎ ↩︎
Vajdi M, et al. (2023). An updated systematic review and dose-response meta-analysis of the randomized controlled trials on the effects of alpha-lipoic acid supplementation on inflammatory biomarkers. International Journal for Vitamin and Nutrition Research. https://pubmed.ncbi.nlm.nih.gov/33827267/ ↩︎
Rahimlou M, et al. (2019). Alpha-lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: A Systematic Review and meta-analysis. Clinical Nutrition ESPEN. https://pubmed.ncbi.nlm.nih.gov/31221283/ ↩︎
Saboori S, et al. (2018). Effects of alpha-lipoic acid supplementation on C-reactive protein level: A systematic review and meta-analysis of randomized controlled clinical trials. Nutrition, Metabolism, and Cardiovascular Diseases. https://pubmed.ncbi.nlm.nih.gov/29753588/ ↩︎
Pires IZ, et al. (2025). Efficacy of Alpha Lipoic Acid Supplementation in Sperm Parameters: A Systematic Review and Meta-Analysis of Randomized Trials. International Braz J Urol. https://pubmed.ncbi.nlm.nih.gov/40327515/ ↩︎ ↩︎
Banihani SA. (2025). Role of Lipoic Acid in Testosterone Production in Males. The World Journal of Men's Health. https://pubmed.ncbi.nlm.nih.gov/38772537/ ↩︎
Abu-Zaid A, et al. (2024). The effect of alpha-lipoic acid supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in individuals with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. Obstetrics & Gynecology Science. https://pubmed.ncbi.nlm.nih.gov/38044616/ ↩︎
Vafaee F, et al. (2025). Alpha-lipoic acid, as an effective agent against toxic elements: a review. Naunyn-Schmiedeberg's Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/39556148/ ↩︎ ↩︎
Ataei M, et al. (2026). Exploring the Role of Alpha Lipoic Acid in the Treatment of Traumatic Brain Injury: Pathways and Perspectives. Neurocritical Care. https://pubmed.ncbi.nlm.nih.gov/41083749/ ↩︎ ↩︎
Mousavi SM, et al. (2019). Effect of alpha-lipoic acid supplementation on lipid profile: A systematic review and meta-analysis of controlled clinical trials. Nutrition. https://pubmed.ncbi.nlm.nih.gov/30471524/ ↩︎
Xie H, et al. (2022). Role of lipoic acid in multiple sclerosis. CNS Neuroscience & Therapeutics. https://pubmed.ncbi.nlm.nih.gov/34964271/ ↩︎
Vakali E, et al. (2022). Effects of Alpha-lipoic Acid Supplementation on Human Diabetic Nephropathy: A Systematic Review and Meta-analysis. Current Diabetes Reviews. https://pubmed.ncbi.nlm.nih.gov/34521329/ ↩︎
Sun F, et al. (2021). Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. BMC Endocrine Disorders. https://pubmed.ncbi.nlm.nih.gov/34465338/ ↩︎
Di Tucci C, et al. (2021). The role of alpha lipoic acid in female and male infertility: a systematic review. Gynecological Endocrinology. https://pubmed.ncbi.nlm.nih.gov/33345661/ ↩︎
Di Tucci C, et al. (2018). Alpha lipoic acid in obstetrics and gynecology. Gynecological Endocrinology. https://pubmed.ncbi.nlm.nih.gov/29726290/ ↩︎ ↩︎
Sharifi-Zahabi E, et al. (2024). Alpha Lipoic Acid Supplementation and Iron Homeostasis: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. International Journal for Vitamin and Nutrition Research. https://pubmed.ncbi.nlm.nih.gov/40134249/ ↩︎ ↩︎